- Home
- IMA vs COCH Comparison
IMA vs COCH Comparison
Compare IMA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMA | COCH |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | 15 | 47 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 47.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMA | COCH |
|---|---|---|
| Price | $6.04 | $0.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $16.00 | $6.00 |
| AVG Volume (30 Days) | ★ 369.6K | 134.2K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.94 | $0.36 |
| 52 Week High | $17.50 | $1.91 |
Technical Indicators
Market Signals| Indicator | IMA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 49.09 |
| Support Level | $5.52 | $0.63 |
| Resistance Level | $7.17 | $0.73 |
| Average True Range (ATR) | 0.36 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 77.12 | 54.61 |
Price Performance
Historical ComparisonAbout IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.